CCM
XENE icon

Consonance Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Consonance Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,979,669
Closed -$22.4M – 38
2020
Q1 		$22.4M Buy
+1,979,669
New +$28.2M 1.67% 22

Other funds holding XENE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Consonance Capital Management's XENE Position: Q2 2020 in Review

Consonance Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2020, closing a stake of 1,979,669 shares — an estimated $22.4M sold.

Consonance Capital Management first reported a position in XENE in Q1 2020 and held it in 1 quarter. The position peaked at $22.4M in Q1 2020. 79 funds tracked by Wall St. Rank hold XENE as of Q2 2020.

  • Consonance Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 1,979,669 Xenon Pharmaceuticals shares in Q2 2020, an estimated $22.4M.
  • Consonance Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Consonance Capital Management's Xenon Pharmaceuticals position peaked at $22.4M in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.